J. Gray

发表

Exogenous control of mammalian gene expression through modulation of RNA self-cleavage

R. D'Amato, R. Mulligan, Laising Yen, 2004, Nature.

diminish the risk for proto-oncogene activation An experimental system for the evaluation of retroviral vector design to

A. Nienhuis, B. Ryu, J. Gray, 2009 .

Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.

J. Gray, A. Davidoff, Y. Bakar, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation.

R. Mulligan, Jeng-Shin Lee, J. Gray, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

707. Retroviral insertion site analysis in rhesus macaques transplanted with CD34+ hematopoietic stem cells transduced with a simian immunodeficiency virus-based lentiviral vector

A. Nienhuis, J. Gray, C. Dunbar, 2004 .

A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

M. Cavazzana‐Calvo, J. Gray, T. Lu, 2010, Blood.

Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.

P. Fagone, A. Nienhuis, J. Gray, 2011, Human gene therapy.

TNNT1 nemaline myopathy: natural history and therapeutic frontier

K. Strauss, J. Gray, M. Lawlor, 2018, Human molecular genetics.

Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells.

J. Gray, Cheng Cheng, G. Neale, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Soluble receptor-mediated selective inhibition of VEGFR and PDGFRβ signaling during physiologic and tumor angiogenesis

C. Kuo, D. McDonald, R. Mulligan, 2008, Proceedings of the National Academy of Sciences.

A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells.

A. Nienhuis, B. Ryu, J. Gray, 2007, Blood cells, molecules & diseases.

of FVII at levels that protect against fatal spontaneous hemorrhage AAV-mediated gene transfer in the perinatal period results in expression

J. Gray, C. Morton, A. Davidoff, 2014 .

AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage

J. Gray, C. Morton, A. Davidoff, 2011, Blood.

Enhancing transduction of the liver by adeno-associated viral vectors

J. Gray, A. Davidoff, J. Mcintosh, 2009, Gene Therapy.

Correction of Murine Sickle Cell Disease Using γ-Globin Lentiviral Vectors to Mediate High-level Expression of Fetal Hemoglobin.

J. Gray, D. Persons, T. Pestina, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Recombinant adeno-associated viral vector production using stable packaging and producer cell lines.

J. Gray, M. Gallagher, R. Snyder, 2002, Methods in enzymology.

transduction of murine and nonhuman primate liver efficient liver-specific human factor IX expression cassette enable highly Self-complementary adeno-associated virus vectors containing a novel

J. Gray, E. Tuddenham, K. Mertens, 2013 .

Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.

J. Gray, A. Davidoff, E. Tuddenham, 2007, Blood.

Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

A. Nienhuis, J. Gray, M. Valentine, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methods.

P. Fagone, A. Nienhuis, J. Gray, 2012, Human gene therapy methods.

Systemic Errors in Quantitative Polymerase Chain Reaction Titration of Self-Complementary Adeno-Associated Viral Vectors and Improved Alternative Methods

P. Fagone, A. Nienhuis, J. Gray, 2011 .

Induction of Neuron-Specific Degradation of Coenzyme A Models Pantothenate Kinase-Associated Neurodegeneration by Reducing Motor Coordination in Mice

P. Fagone, J. Rehg, J. Gray, 2015, PloS one.

variant administration of rAAV vector encoding a novel human factor VIII Therapeutic levels of FVIII following a single peripheral vein

P. Fagone, A. Nienhuis, O. Christophe, 2014 .

Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

P. Fagone, A. Nienhuis, O. Christophe, 2013, Blood.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Michael Recht, Pratima Chowdary, Deepak Raj, 2014, The New England journal of medicine.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Pratima Chowdary, Savita Rangarajan, Cecilia Rosales, 2011, The New England journal of medicine.

Developments in the treatment of hemophilia B: focus on emerging gene therapy

Amit C Nathwani, J. Gray, A. Davidoff, 2013, The Application of Clinical Genetics.

Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B

M. Kay, A. Nienhuis, J. Gray, 2010 .

Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.

Geoffrey Kemball-Cook, Jenny McIntosh, Yunyu Spence, 2006, Blood.

Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system.

K. Keyvanfar, A. Nienhuis, J. Gray, 2004, Blood.

Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps

A. Souquette, P. Thomas, J. Gray, 2022, Molecular therapy. Methods & clinical development.

Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency

L. Notarangelo, J. Gray, D. Kuhns, 2016, Science Translational Medicine.

Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral Vector

John T. Gray, J. Gray, T. Lu, 2013, PloS one.

An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.

A. Nienhuis, B. Ryu, J. Gray, 2008, Blood.

Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity

C. Pui, Y. Li, J. Gray, 2014, Leukemia.

81. Development of a Second Generation Stable Lentiviral Packaging Cell Line in Support of Clinical Gene Transfer Protocols

J. Gray, B. Sorrentino, R. Throm, 2015 .

Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line.

Perdeep K. Mehta, J. Gray, B. Sorrentino, 2012, Human gene therapy methods.

Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

J. Gray, B. Sorrentino, R. Throm, 2009, Blood.

Nfix is a novel regulator of murine hematopoietic stem and progenitor cell survival.

S. McKinney-Freeman, D. Finkelstein, J. Gray, 2013, Blood.

Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins.

A. Nienhuis, J. Gray, D. Persons, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.

J. Gray, D. Persons, T. Pestina, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Design and construction of functional AAV vectors.

J. Gray, S. Zolotukhin, 2011, Methods in molecular biology.

expression of human FIX in nonhuman primates of self-complementary AAV vector results in stable therapeutic Safe and efficient transduction of the liver after peripheral vein infusion

J. Gray, A. Davidoff, E. Tuddenham, 2013 .

Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock.

J. Gray, A. Davidoff, A. Nathwani, 2004, Journal of virological methods.

Preclinical dose-finding study with a liver-tropic, recombinant AAV-2/8 vector in the mouse model of galactosialidosis.

A. Nienhuis, J. Gray, J. Allay, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Antitumor efficacy of AAV-mediated systemic delivery of interferon-β

J. Gray, A. Davidoff, C. Ng, 2006, Cancer Gene Therapy.

Determining the Minimally Effective Dose of a Clinical Candidate AAV Vector in a Mouse Model of Crigler-Najjar Syndrome

J. Gray, James M. Wilson, P. Bell, 2018, Molecular therapy. Methods & clinical development.

Adeno-Associated Virus Vector-Mediated Systemic Delivery of IFN-β Combined with Low-Dose Cyclophosphamide Affects Tumor Regression in Murine Neuroblastoma Models

J. Gray, A. Davidoff, A. Nathwani, 2005, Clinical Cancer Research.

Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma.

J. Gray, A. Davidoff, M. Danks, 2007, Journal of pediatric surgery.

False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector.

S. Hughes, J. Coffin, J. Gray, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy.

R. Grange, D. Mack, J. Gray, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

AAV-mediated gene transfer restores a normal muscle transcriptome in a canine model of X-linked myotubular myopathy

R. Grange, D. Mack, J. Gray, 2018, bioRxiv.

Laboratory Safety for Oncogene-Containing Retroviral Vectors

J. Gray, 2011 .

TCRP OVERSIGHT AND PROJECT SELECTION COMMITTEE

Kirk T. Steudle, Michael W. Hancock, Linda J. Bohlinger, 2011 .

The Application of Clinical Genetics Dovepress Developments in the Treatment of Hemophilia B: Focus on Emerging Gene Therapy

J. Gray, A. Davidoff, A. Nathwani, 2022 .

Globin Lentiviral Vector Insertions Can Perturb the Expression of Endogenous Genes in β-thalassemic Hematopoietic Cells.

J. Gray, Cheng Cheng, G. Neale, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

M. Kay, A. Nienhuis, J. Gray, 2014, The New England journal of medicine.